466 related articles for article (PubMed ID: 29909548)
1. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW
Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548
[TBL] [Abstract][Full Text] [Related]
2. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
[TBL] [Abstract][Full Text] [Related]
3. Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis.
Mariet C; Castel D; Grill J; Saffroy R; Dangouloff-Ros V; Boddaert N; Llamas-Guttierrez F; Chappé C; Puget S; Hasty L; Chrétien F; Métais A; Varlet P; Tauziède-Espariat A
Acta Neuropathol Commun; 2022 Sep; 10(1):137. PubMed ID: 36104744
[TBL] [Abstract][Full Text] [Related]
4. EZH2 inhibitory protein (EZHIP/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations.
Nambirajan A; Sharma A; Rajeshwari M; Boorgula MT; Doddamani R; Garg A; Suri V; Sarkar C; Sharma MC
Brain Tumor Pathol; 2021 Jan; 38(1):30-40. PubMed ID: 33130928
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity within the PF-EPN-B ependymoma subgroup.
Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
[TBL] [Abstract][Full Text] [Related]
6. PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism.
Jain SU; Do TJ; Lund PJ; Rashoff AQ; Diehl KL; Cieslik M; Bajic A; Juretic N; Deshmukh S; Venneti S; Muir TW; Garcia BA; Jabado N; Lewis PW
Nat Commun; 2019 May; 10(1):2146. PubMed ID: 31086175
[TBL] [Abstract][Full Text] [Related]
7. Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors.
Han J; Yu M; Bai Y; Yu J; Jin F; Li C; Zeng R; Peng J; Li A; Song X; Li H; Wu D; Li L
Cancer Cell; 2020 Dec; 38(6):844-856.e7. PubMed ID: 33186520
[TBL] [Abstract][Full Text] [Related]
8. H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2.
Jain SU; Rashoff AQ; Krabbenhoft SD; Hoelper D; Do TJ; Gibson TJ; Lundgren SM; Bondra ER; Deshmukh S; Harutyunyan AS; Juretic N; Jabado N; Harrison MM; Lewis PW
Mol Cell; 2020 Nov; 80(4):726-735.e7. PubMed ID: 33049227
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
[TBL] [Abstract][Full Text] [Related]
10. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
11. H3 K27M mutations are extremely rare in posterior fossa group A ependymoma.
Ryall S; Guzman M; Elbabaa SK; Luu B; Mack SC; Zapotocky M; Taylor MD; Hawkins C; Ramaswamy V
Childs Nerv Syst; 2017 Jul; 33(7):1047-1051. PubMed ID: 28623522
[TBL] [Abstract][Full Text] [Related]
12. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
Jenseit A; Camgöz A; Pfister SM; Kool M
Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups.
Łastowska M; Matyja E; Sobocińska A; Wojtaś B; Niemira M; Szałkowska A; Krętowski A; Karkucińska-Więckowska A; Kaleta M; Ejmont M; Tarasińska M; Perek-Polnik M; Dembowska-Bagińska B; Pronicki M; Grajkowska W; Trubicka J
J Pathol Clin Res; 2021 Nov; 7(6):565-576. PubMed ID: 34314101
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma.
Michealraj KA; Kumar SA; Kim LJY; Cavalli FMG; Przelicki D; Wojcik JB; Delaidelli A; Bajic A; Saulnier O; MacLeod G; Vellanki RN; Vladoiu MC; Guilhamon P; Ong W; Lee JJY; Jiang Y; Holgado BL; Rasnitsyn A; Malik AA; Tsai R; Richman CM; Juraschka K; Haapasalo J; Wang EY; De Antonellis P; Suzuki H; Farooq H; Balin P; Kharas K; Van Ommeren R; Sirbu O; Rastan A; Krumholtz SL; Ly M; Ahmadi M; Deblois G; Srikanthan D; Luu B; Loukides J; Wu X; Garzia L; Ramaswamy V; Kanshin E; Sánchez-Osuna M; El-Hamamy I; Coutinho FJ; Prinos P; Singh S; Donovan LK; Daniels C; Schramek D; Tyers M; Weiss S; Stein LD; Lupien M; Wouters BG; Garcia BA; Arrowsmith CH; Sorensen PH; Angers S; Jabado N; Dirks PB; Mack SC; Agnihotri S; Rich JN; Taylor MD
Cell; 2020 Jun; 181(6):1329-1345.e24. PubMed ID: 32445698
[TBL] [Abstract][Full Text] [Related]
15. Anatomic Neuroimaging Characteristics of Posterior Fossa Type A Ependymoma Subgroups.
Sabin ND; Hwang SN; Klimo P; Chambwe N; Tatevossian RG; Patni T; Li Y; Boop FA; Anderson E; Gajjar A; Merchant TE; Ellison DW
AJNR Am J Neuroradiol; 2021 Dec; 42(12):2245-2250. PubMed ID: 34674998
[TBL] [Abstract][Full Text] [Related]
16. Evidence of H3 K27M mutations in posterior fossa ependymomas.
Gessi M; Capper D; Sahm F; Huang K; von Deimling A; Tippelt S; Fleischhack G; Scherbaum D; Alfer J; Juhnke BO; von Hoff K; Rutkowski S; Warmuth-Metz M; Chavez L; Pfister SM; Pietsch T; Jones DT; Sturm D
Acta Neuropathol; 2016 Oct; 132(4):635-7. PubMed ID: 27539613
[No Abstract] [Full Text] [Related]
17. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.
Fukuoka K; Kanemura Y; Shofuda T; Fukushima S; Yamashita S; Narushima D; Kato M; Honda-Kitahara M; Ichikawa H; Kohno T; Sasaki A; Hirato J; Hirose T; Komori T; Satomi K; Yoshida A; Yamasaki K; Nakano Y; Takada A; Nakamura T; Takami H; Matsushita Y; Suzuki T; Nakamura H; Makino K; Sonoda Y; Saito R; Tominaga T; Matsusaka Y; Kobayashi K; Nagane M; Furuta T; Nakada M; Narita Y; Hirose Y; Ohba S; Wada A; Shimizu K; Kurozumi K; Date I; Fukai J; Miyairi Y; Kagawa N; Kawamura A; Yoshida M; Nishida N; Wataya T; Yamaoka M; Tsuyuguchi N; Uda T; Takahashi M; Nakano Y; Akai T; Izumoto S; Nonaka M; Yoshifuji K; Kodama Y; Mano M; Ozawa T; Ramaswamy V; Taylor MD; Ushijima T; Shibui S; Yamasaki M; Arai H; Sakamoto H; Nishikawa R; Ichimura K;
Acta Neuropathol Commun; 2018 Dec; 6(1):134. PubMed ID: 30514397
[TBL] [Abstract][Full Text] [Related]
18. Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome.
Jünger ST; Andreiuolo F; Mynarek M; Dörner E; Zur Mühlen A; Rutkowski S; von Bueren AO; Pietsch T
Childs Nerv Syst; 2020 Nov; 36(11):2693-2700. PubMed ID: 32474813
[TBL] [Abstract][Full Text] [Related]
19. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
[TBL] [Abstract][Full Text] [Related]
20. Recurrent pediatric infratentorial ependymomas: a systematic review and meta-analysis on outcomes and molecular classification.
Montgomery EY; Thirunavu V; Pagadala M; Shlobin NA; Plant-Fox AS; Lam S; DeCuypere M
J Neurosurg Pediatr; 2023 Feb; 31(2):132-142. PubMed ID: 36433871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
